Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth From $17.02 Billion In 2026 To $45.08 Billion By 2030 At A CAGR Of 27.6%

The market for treating transthyretin amyloid cardiomyopathy (attr-cm) has experienced remarkable expansion recently. Projections indicate a substantial increase from $13.29 billion in 2025 to $17.03 billion in 2026, reflecting a compound annual growth rate (CAGR) of 28.1%. Factors contributing to this growth during the preceding period include heightened awareness of the condition among cardiologists, a rise in the identification of uncommon cardiomyopathies, the introduction of specific drug treatments, the proliferation of specialized cardiac care facilities, and advancements in genetic testing methods.

The market for transthyretin amyloid cardiomyopathy (attr-cm) treatments is projected to experience remarkable expansion over the coming years, reaching an estimated value of $45.09 billion by 2030, fueled by a compound annual growth rate of 27.6%. This anticipated surge is largely driven by the progressive adoption of personalized medicine strategies, advancements in gene-silencing therapies of the next generation, increased capital allocation towards rare disease drug development, enhanced patient access to sophisticated cardiac diagnostic tools, and a heightened emphasis on therapeutic interventions that modify the disease’s course. Key developments foreseen within this timeframe involve a greater embrace of transthyretin stabilizer therapies, escalating utilization of RNAi-based treatment methodologies, a more concerted effort towards early detection and ongoing disease management, the broadening scope of individualized treatment plans, and augmented investment in the research of rare cardiac conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Demand Drivers Creating New Revenue Opportunities

The expanding incidence of long-term health issues is anticipated to be a significant catalyst for the advancement of the market dedicated to treating transthyretin amyloid cardiomyopathy (ATTR-CM). These enduring ailments, characterized by their gradual onset and prolonged duration, often necessitate ongoing medical intervention. A confluence of factors, including an aging demographic, increasingly inactive lifestyles, suboptimal dietary habits, escalating rates of obesity, and heightened exposure to environmental contaminants, contributes to the heightened occurrence of these chronic conditions. Therapies for ATTR-CM play a crucial role in addressing these conditions by reinforcing the stability of transthyretin, thereby diminishing the accumulation of amyloid deposits, enhancing cardiac performance, and mitigating the manifestation of symptoms. To illustrate, data from the U.S. Centers for Disease Control and Prevention (CDC) indicated that in 2023, a substantial 76.4% of American adults, approximating 194 million individuals, contended with at least one chronic condition. This prevalence extended to 59.5% of younger adults, 78.4% of middle-aged individuals, and a commanding 93.0% of older adults. Consequently, the increasing ubiquity of chronic diseases is directly fueling the growth trajectory of the ATTR-CM treatment sector.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Categorization By Product Type And Application

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market covered in this report is segmented –

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types

2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Transthyretin Stabilizers: Tafamidis, Diflunisal

2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen

3) By RNAi Therapy: Patisiran, Vutrisiran

4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends Driving Strategic Industry Expansion

In the transthyretin amyloid cardiomyopathy (ATTR-CM) therapeutic arena, leading pharmaceutical entities are dedicating efforts towards pioneering novel treatment modalities for ATTR-CM. These advancements include the creation of orally administered prescription medications designed to specifically target and stabilize transthyretin (TTR) proteins or to diminish the accumulation of amyloid fibrils within the cardiac muscle. Oral prescription drugs are those dispensed under the guidance of a medical professional and ingested via the mouth, commonly presented as pills, capsules, or liquid formulations. An illustrative example occurred in November 2024 when BridgeBio Pharma Inc., a biotechnology firm headquartered in the United States, secured U.S. Food and Drug Administration approval for Attruby, also known as acoramidis, intended for the management of ATTR-CM in adult patients. This pharmaceutical agent functions by stabilizing the TTR protein, thereby leading to a reduction in cardiac fatalities and hospital admissions. Evidence from clinical investigations demonstrates its favorable safety profile and its capacity to deliver swift therapeutic advantages by addressing the fundamental etiology of the condition.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Company Landscape And Strategic Competition

Major companies operating in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc

Access The Complete Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model